The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)

D. Singh, E. D. Bateman, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Manchester, London, United Kingdom; Cape Town, South Africa; Barcelona, Spain; , United States Of America)

Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Session: Bronchodilators in asthma and COPD
Session type: Thematic Poster Session
Number: 875
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Singh, E. D. Bateman, P. W. Jones, A. Agusti, R. Lamarca, G. de Miquel, C. Caracta, E. Garcia Gil (Manchester, London, United Kingdom; Cape Town, South Africa; Barcelona, Spain; , United States Of America). The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). Eur Respir J 2011; 38: Suppl. 55, 875

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011


Efficacy of tiotropium bromide in patients with chronic obstructive pulmonary disease of varying severity
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008


Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain
Source: Eur Respir J 2006; 28: Suppl. 50, 683s
Year: 2006

The comparison of ipratropium bromide in parallel group study in adults with chronic obstructive pulmonary disease (COPD) and gastroduodenal ulcer
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial
Source: Eur Respir J 2002; 19: 936-943
Year: 2002



Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 639-644
Year: 2002



Effects of tiotropium bromide in exercise tolerance in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005

A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001

Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001

Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromide, alone and in combination?
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001

Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Source: Eur Respir J 2002; 19: 217-224
Year: 2002



Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003



The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
Source: Eur Respir J 2003; 21: 68-73
Year: 2003